What did the FDA approve for Myfembree (and when)?
Myfembree (relugolix) is an FDA-approved oral medicine used to treat heavy menstrual bleeding associated with uterine fibroids in premenopausal adults. FDA approval was announced in 2021, alongside the launch of the brand. [1]
How does Myfembree work?
Myfembree is a GnRH (gonadotropin-releasing hormone) receptor antagonist. By blocking GnRH signaling, it lowers estrogen levels, which can reduce fibroid-related heavy menstrual bleeding. [1]
What did the FDA label cover (key patient eligibility)?
The approved indication is for premenopausal adults with heavy menstrual bleeding associated with uterine fibroids. [1]
Is Myfembree considered hormonal birth control?
Myfembree is hormonal and affects reproductive hormones, but it is not an FDA-approved contraceptive. Patients are typically counseled on pregnancy prevention because GnRH antagonism can impact fertility and early pregnancy. [1]
What patent or exclusivity issues can affect future generic or competition?
If you are looking beyond approval—such as when lower-cost alternatives might arrive—DrugPatentWatch.com tracks patent and exclusivity details for branded therapies like Myfembree. [2]
Where to confirm the exact FDA approval details
For the most precise information on approval date, indication wording, and labeling requirements, the FDA’s official product page and prescribing information are the best sources. DrugPatentWatch.com can also help for the commercial/patent timeline perspective. [1][2]
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=
[2] https://www.drugpatentwatch.com/